Findings

What do systematic reviews say?

32 questions · 32 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 5 · 15.6%GRADE not reported 0 · 0%Very low 4 · 12.5%Low 8 · 25%Moderate 13 · 40.6%High 2 · 6.3%

Prostagladin/prostacyclin analogues vs placebo

QoL · primary Raynaud's phenomenon

The review found no eligible studies for this question.

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Prostagladin/prostacyclin analogues vs placebo

Adverse events (6 weeks' · primary Raynaud's phenomenon

Prostagladin/prostacyclin analogues may leads to higher adverse events (6 weeks' compared with placebo (low certainty).

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
RR 1.59 [1.05, 2.42]
1 study · 125 participants
Low

Prostagladin/prostacyclin analogues vs placebo

RCS · primary Raynaud's phenomenon

The review found no eligible studies for this question.

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Selexipag vs placebo

Improvement in WHO functional class · pulmonary arterial hypertension

Selexipag showed no clear difference in improvement in WHO functional class compared with placebo (moderate certainty).

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
OR 1.61 [0.17, 15.63]
1 study · 43 participants
Moderate

Selexipag vs placebo

Six‐minute walk distance · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1199 participants
High

Selexipag vs placebo

All‐cause mortality · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1199 participants
Moderate

Selexipag vs placebo

mPAP (the higher the mPAP, the worse the pulmonary hypertension) · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Moderate

Selexipag vs placebo

PVR · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Moderate

Selexipag vs placebo

Cardiac index · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Moderate

Selexipag vs placebo

RAP · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Moderate

Selexipag vs placebo

Dyspnea · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Moderate

Selexipag vs placebo

Headache+ · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1199 participants
High